SCHEMBL457464

SCHEMBL457464

CCCCOC(=O)NCCCC[C@H](N)C(=O)O

nearest known ligand 0.57

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
ACHE P22303 14/20 0.57
DPP7 Q9UHL4 1/20 0.50
EPHX2 P34913 2/20 0.48
GNAI3 P08754 1/20 0.48
GNAO1 P09471 1/20 0.48
GNAI1 P63096 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7534573 1.00 ACHE (0.57) ACHEDPP7EPHX2GNAI3GNAO1
SCHEMBL7804987 0.94 ACHE (0.62) ACHEDPP7EPHX2GNAI3GNAO1
SCHEMBL7803301 0.94 ACHE (0.62) ACHEDPP7EPHX2GNAI3GNAO1
SCHEMBL7804961 0.94 ACHE (0.62) ACHEDPP7EPHX2GNAI3GNAO1
SCHEMBL7797292 0.94 ACHE (0.62) ACHEDPP7EPHX2GNAI3GNAO1
SCHEMBL9061677 0.90 ACHE (0.64) ACHEEPHX2
SCHEMBL16053917 0.90 ACHE (0.56) ACHEDPP7EPHX2GNAI3GNAO1
SCHEMBL16054345 0.90 ACHE (0.56) ACHEDPP7EPHX2GNAI3GNAO1
SCHEMBL17852152 0.88 ACHE (0.54) ACHEDPP7
SCHEMBL20192789 0.87 GSR (0.56) ACHEDPP7GNAI3GNAO1GNAI1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130065272-A1 Synthesis of Site Specifically-Linked Ubiquitin MEDICAL RESEARCH COUNCIL (GB) 2013-03-14 US claimed
EP-2046733-A1 PROCESS FOR THE PREPARATION OF EPSILON-ALKOXYCARBONYLLYSINES AND THEIR ANALOGUES F.I.S. FABBRICA ITALIANA SINTETICI S.P.A. (IT) 2009-04-15 EP claimed
WO-2008014811-A1 PROCESS FOR THE PREPARATION OF ε-ALKOXYCARBONYLLYSINES AND THEIR ANALOGUES F.I.S. FABBRICA ITALIANA SINTETICI S.P.A (IT) 2008-02-07 WO claimed
EP-1088020-A1 FUNCTIONALISED POLYMERS OF ALPHA-AMINO ACIDS AND THE METHOD OF PREPARATION THEREOF USTAV MAKROMOLEKULARNI CHEMIE AKADEMIE VED CESKE REPUBLIKY (CZ) 2001-04-04 EP claimed
WO-1999064495-A1 FUNCTIONALISED POLYMERS OF α-AMINO ACIDS AND THE METHOD OF PREPARATION THEREOF ÚSTAV MAKROMOLEKULÁRNÍ CHEMIE AKADEMIE VĚD ČESKÉ REPUBLIKY (CZ) 1999-12-16 WO claimed
EP-4176050-A1 PYRROLYSYL-TRNA SYNTHETASE VARIANTS AND USES THEREOF enGenes Biotech GmbH (AT) 2023-05-10 EP disclosed
CN-113880849-B Chiral lysine modified zinc phthalocyanine and preparation method and application thereof 南京师范大学 2022-12-16 CN disclosed
WO-2022003142-A1 PYRROLYSYL-tRNA SYNTHETASE VARIANTS AND USES THEREOF ENGENES BIOTECH GMBH (AT) 2022-01-06 WO disclosed
EP-3720472-A1 INJECTABLE SOLUTION AT PH 7 COMPRISING AT LEAST ONE BASAL INSULIN HAVING A PI OF BETWEEN 5.8 AND 8.5 AND A COPOLYAMINO ACID CARRYING CARBOXYLATE CHARGES AND HYDROPHOBIC RADICALS Adocia (FR) 2020-10-14 EP disclosed
EP-3607326-A1 METHODS AND REAGENTS FOR ANALYZING PROTEIN-PROTEIN INTERFACES Revolution Medicines, Inc. (US) 2020-02-12 EP disclosed
WO-2019110625-A1 INJECTABLE SOLUTION AT PH 7 COMPRISING AT LEAST ONE BASAL INSULIN HAVING A PI OF BETWEEN 5.8 AND 8.5 AND A COPOLYAMINO ACID CARRYING CARBOXYLATE CHARGES AND HYDROPHOBIC RADICALS ADOCIA (FR) 2019-06-13 WO disclosed
WO-2019010164-A1 EVOLUTION OF TRNA SYNTHETASES PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2019-01-10 WO disclosed
WO-1999002549-A1 POLYOL-AMINO ACID COMPOUNDS HAVING ANTI-HELICOBACTER PYLORI ACTIVITY TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1999-01-21 WO disclosed
WO-1998046786-A1 COMBINATORIAL LIBRARIES OF PEPTIDOMIMETIC AMINOTHIOETHER ACIDS ELI LILLY AND COMPANY (US) 1998-10-22 WO disclosed
EP-0817796-A1 CYCLIC PEPTIDE NUCLEI AND DERIVATIVES THEREOF FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1998-01-14 EP disclosed
WO-1996030399-A1 CYCLIC PEPTIDE NUCLEI AND DERIVATIVES THEREOF FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1996-10-03 WO disclosed
EP-0722456-A1 ANTIFUNGAL COMPOSITIONS BTG INTERNATIONAL LIMITED (GB) 1996-07-24 EP disclosed
EP-0672130-A1 PEPTIDE CORRESPONDING TO CD44 EXON 6, ANTIBODIES SPECIFIC FOR SAID PEPTIDE AND USE OF THESE ANTIBODIES FOR DIAGNOSIS OF TUMORS ISIS INNOVATION LIMITED (GB) 1995-09-20 EP disclosed
WO-1995009867-A1 ANTIFUNGAL COMPOSITIONS BRITISH TECHNOLOGY GROUP LIMITED (GB) 1995-04-13 WO disclosed
WO-1994012631-A1 PEPTIDE CORRESPONDING TO CD44 EXON 6, ANTIBODIES SPECIFIC FOR SAID PEPTIDE AND USE OF THESE ANTIBODIES FOR DIAGNOSIS OF TUMORS ISIS INNOVATION LIMITED (GB) 1994-06-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130065272-A1 Synthesis of Site Specifically-Linked Ubiquitin SUMO2, STUB1, UBE3C ACHE 3258/4885DPP7 530/4885EPHX2 2590/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.